Yu Fa Wei

Director/Board Member at Genfleet Therapeutics (Shanghai), Inc.

Commercial Services

Profile

Yu Fa Wei currently works in at least one company called Genfleet Therapeutics (Shanghai), Inc. where he currently holds the position of Member-Supervisory Board.

Yu Fa Wei active positions

Companies	Position	Start
Genfleet Therapeutics (Shanghai), Inc. Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017.	Director/Board Member	-

All active positions of Yu Fa Wei

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Yu Fa Wei's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Genfleet Therapeutics (Shanghai), Inc. Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017.	Commercial Services